340 related articles for article (PubMed ID: 35769474)
1. Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.
Cao P; Xu W; Zhang L
Front Immunol; 2022; 13():928621. PubMed ID: 35769474
[TBL] [Abstract][Full Text] [Related]
2. Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature.
Kremer N; Snast I; Cohen ES; Hodak E; Mimouni D; Lapidoth M; Mazor S; Levi A
Am J Clin Dermatol; 2019 Apr; 20(2):209-216. PubMed ID: 30421306
[TBL] [Abstract][Full Text] [Related]
3. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.
Seyed Jafari SM; Feldmeyer L; Bossart S; Simon D; Schlapbach C; Borradori L
Front Immunol; 2020; 11():611549. PubMed ID: 33584689
[TBL] [Abstract][Full Text] [Related]
4. Biological treatment for bullous pemphigoid.
Oren-Shabtai M; Mimouni D; Nosrati A; Atzmony L; Kaplan B; Barzilai A; Baum S
Front Immunol; 2023; 14():1157250. PubMed ID: 37180101
[TBL] [Abstract][Full Text] [Related]
5. Clinical effect of omalizumab as an adjuvant treatment to rituximab in patient with refractory bullous pemphigoid.
Kwon IJ; Kim T; Yoo DS; Min S; Kim SC; Kim JH
J Dermatol; 2023 May; 50(5):705-709. PubMed ID: 36514846
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab for the treatment of prurigo nodularis: A systematic review.
Cao P; Xu W; Jiang S; Zhang L
Front Immunol; 2023; 14():1092685. PubMed ID: 36742321
[TBL] [Abstract][Full Text] [Related]
7. Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review.
Liang J; Abulikemu K; Maolidan ; Hu F; Zhao J; Qiu Y; Wang Q; Sang Y; Hong Y; Kang X
Int Immunopharmacol; 2023 Mar; 116():109788. PubMed ID: 36731156
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature.
Oren-Shabtai M; Kremer N; Lapidoth M; Sharon E; Atzmony L; Nosrati A; Hodak E; Mimouni D; Levi A
Drugs Aging; 2021 Feb; 38(2):125-136. PubMed ID: 33230804
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of Efficacy and Safety.
D'Aguanno K; Gabrielli S; Ouchene L; Muntyanu A; Ben-Shoshan M; Zhang X; Iannattone L; Netchiporouk E
J Cutan Med Surg; 2022; 26(4):404-413. PubMed ID: 35379011
[TBL] [Abstract][Full Text] [Related]
10. Bullous Diseases.
Corbaux C; Joly P
Curr Probl Dermatol; 2018; 53():64-69. PubMed ID: 29131038
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.
Yan T; Xie Y; Liu Y; Shan Y; Wu X; Wang J; Zuo YG; Zhang Z
Front Immunol; 2023; 14():1194088. PubMed ID: 37575240
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Dupilumab in Patients With Bullous Pemphigoid.
Zhao L; Wang Q; Liang G; Zhou Y; Yiu N; Yang B; Zhang G; Li W; Feng S; Shang P; Chen X; Zhu X; Zheng J; Pan M; Wang M
JAMA Dermatol; 2023 Sep; 159(9):953-960. PubMed ID: 37531116
[TBL] [Abstract][Full Text] [Related]
13. Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT.
Murrell DF; Joly P; Werth VP; Ujiie H; Worm M; Mangold AR; Avetisova E; Maloney J; Laws E; Mortensen E; Dubost-Brama A; Shabbir A
Adv Ther; 2024 Jul; 41(7):2991-3002. PubMed ID: 38443648
[TBL] [Abstract][Full Text] [Related]
14. IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid.
James T; Salman S; Stevenson B; Bundell C; Kelly G; Nolan D; John M
Clin Immunol; 2019 Jan; 198():54-56. PubMed ID: 30557620
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.
Zhang Y; Xu Q; Chen L; Chen J; Zhang J; Zou Y; Gong T; Ji C
Front Immunol; 2021; 12():738907. PubMed ID: 34721404
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of biological agents for pemphigoid: a systematic review and meta-analysis.
Lin Z; Zhao Y; Li F; Li J; Huang X
Int J Dermatol; 2023 Aug; 62(8):1000-1008. PubMed ID: 37212599
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study.
Huang D; Zhang Y; Yu Y; Jiang Y; Kong L; Ding Y; Shi Y; Gao Y
Int Immunopharmacol; 2023 Dec; 125(Pt A):111157. PubMed ID: 37925949
[TBL] [Abstract][Full Text] [Related]
18. Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.
Alexandre M; Bohelay G; Gille T; Le Roux-Villet C; Soued I; Morin F; Caux F; Grootenboer-Mignot S; Prost-Squarcioni C
Front Immunol; 2022; 13():874108. PubMed ID: 35514989
[TBL] [Abstract][Full Text] [Related]
19. Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid.
Yang J; Gao H; Zhang Z; Tang C; Chen Z; Wang L; Yang F; Chen S; He S; Liu S; Tang L; Xu Y; Hu Y; Ma L; Zhao Y; Luo X
Dermatol Ther; 2022 Aug; 35(8):e15648. PubMed ID: 35715972
[TBL] [Abstract][Full Text] [Related]
20. Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments.
Bilgiç Temel A; Bassorgun CI; Akman-Karakaş A; Alpsoy E; Uzun S
Case Rep Dermatol; 2017; 9(1):38-44. PubMed ID: 28413387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]